Belgian Beverage Stock News

Cmb.Tech (ENXTBR:CMBT) is grabbing the spotlight as a series of material updates hit the wires: the company just announced the resignation of its chairman Marc Saverys from the Supervisory Board, with Patrick de Brabandere stepping in, along with the appointment of Gudrun Janssens as an independent member. In addition to these board changes, Cmb.Tech also affirmed an interim dividend payout of USD 0.05 per share, sharpening focus on its shareholder return strategy. For investors deciding what...

Belysse Group ( EBR:BELYS ) First Half 2025 Results Key Financial Results Revenue: €134.6m (down 7.0% from 1H 2024...

There wouldn't be many who think Anheuser-Busch InBev SA/NV's ( EBR:ABI ) price-to-earnings (or "P/E") ratio of 16.5x...

Compagnie du Bois Sauvage ( EBR:COMB ) First Half 2025 Results Key Financial Results Revenue: €127.5m (up 2.2% from 1H...

Soft earnings didn't appear to concern Iep Invest, NV's ( EBR:IEP ) shareholders over the last week. Our analysis...

Key Insights Significant control over Syensqo by retail investors implies that the general public has more power to...

Sofina Société Anonyme's ( EBR:SOF ) price-to-earnings (or "P/E") ratio of 20.2x might make it look like a sell right...

Even though DEME Group NV's ( EBR:DEME ) recent earnings release was robust, the market didn't seem to notice. Our...

Campine NV ( EBR:CAMB ) announced strong profits, but the stock was stagnant. Our analysis suggests that this might be...

A lackluster earnings announcement from SCR-Sibelco N.V. ( EBR:094426466 ) last week didn't sink the stock price...

Inclusio SA's ( EBR:INCLU ) recent weak earnings report didn't cause a big stock movement. However, we believe that...

Compagnie d'Entreprises CFE SA's ( EBR:CFEB ) solid earnings announcement recently didn't do much to the stock price...

SCR-Sibelco ( EBR:094426466 ) First Half 2025 Results Key Financial Results Revenue: €1.15b (up 7.0% from 1H 2024). Net...

argenx SE recently announced positive topline results from the pivotal ADAPT SERON study, showing that VYVGART® achieved statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living for AChR-Ab seronegative gMG patients compared to placebo. This marks a potential milestone as the company prepares to seek FDA approval for expanded labeling, which could allow VYVGART to be used across all adult seronegative gMG patient subtypes for the first...

It's not a stretch to say that Cenergy Holdings SA's ( EBR:CENER ) price-to-earnings (or "P/E") ratio of 15.8x right...

Key Insights Viohalco's significant insider ownership suggests inherent interests in company's expansion A total of 2...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

VGP NV's ( EBR:VGP ) healthy profit numbers didn't contain any surprises for investors. We believe that shareholders...

Ion Beam Applications ( EBR:IBAB ) First Half 2025 Results Key Financial Results Revenue: €304.9m (up 48% from 1H...

D'Ieteren Group SA's ( EBR:DIE ) price-to-earnings (or "P/E") ratio of 26.7x might make it look like a strong sell...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...

Key Insights The considerable ownership by individual investors in NV Bekaert indicates that they collectively have a...

ageas ( EBR:AGS ) First Half 2025 Results Key Financial Results Revenue: €4.41b (up 2.3% from 1H 2024). Net income...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...